Who is sponsoring NCT01962116?

NCT01962116 is sponsored by Centre Hospitalier Universitaire Dijon.

What drugs are being tested in NCT01962116?

Interventions in NCT01962116: Citrate 4%, unfractionated heparin.

What condition does NCT01962116 study?

NCT01962116 studies Patients With Acute Renal Insufficiency.

Is NCT01962116 still recruiting?

NCT01962116 is currently completed. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT01962116: VERROU-REA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU

Completed Phase 3 Last updated 9 February 2026

What this trial tests

Phase 3 trial testing Citrate 4% in Patients With Acute Renal Insufficiency in 405 participants. Completed in 31 December 2016.

Timeline

14 June 2013

Primary endpoint
1 April 2016

31 December 2016

Quick facts

Lead sponsor	Centre Hospitalier Universitaire Dijon
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	405
Start date	14 June 2013
Primary completion	1 April 2016
Estimated completion	31 December 2016
Sites	1 location across France

Drugs / interventions tested

Citrate 4% — full drug profile →
unfractionated heparin — full drug profile →

Conditions studied

Patients With Acute Renal Insufficiency — all drugs for Patients With Acute Renal Insufficiency →

Sponsor

Centre Hospitalier Universitaire Dijon

Who can join

18 and older, any sex, with Patients With Acute Renal Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After obtaining written informed consent and inclusion, patients will be randomised into 2 groups for the type of dialysis catheter lock: * The first group will have a citrate lock * The second group will have a heparin lock Patients will be stratified according to the centre and type of Renal Replacement Therapy (RRT) continuous or intermittent. The daily surveillance of patients will not be different from the usual surveillance of patients on Renal Replacement Therapy. The hemodialysis catheters used will be specific Renal Replacement Therapy catheters. The decision to withdraw the catheter will be made by the investigator and based on clinical criteria (complications related to the catheter, termination of Renal Replacement Therapy…)

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Trisodium citrate 4% versus heparin as a catheter lock for non-tunneled hemodialysis catheters in critically ill patients: a multicenter, randomized clinical trial.
Quenot JP, Helms J, Bourredjem A, Dargent A, et al · · 2019 · cited 21× · PMID 31264073 · DOI 10.1186/s13613-019-0553-4
Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.
López-Briz E, Ruiz Garcia V, Cabello JB, Bort-Martí S, et al · · 2022 · cited 15× · PMID 35849083 · DOI 10.1002/14651858.cd008462.pub4
Quasi-experimental study of sodium citrate locks and the risk of acute hemodialysis catheter infection among critically ill patients.
Parienti JJ, Deryckère S, Mégarbane B, Valette X, et al · · 2014 · cited 13× · PMID 24982071 · DOI 10.1128/aac.03079-14
Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial.
Bruyère R, Soudry-Faure A, Capellier G, Binquet C, et al · · 2014 · cited 6× · PMID 25409678 · DOI 10.1186/1745-6215-15-449

Verify or expand the search:

Other trials of Citrate 4%

Trials testing the same drug.

NCT03114722 — Citrate 4% Versus Heparinised Saline in Preventing Peripherally Inserted Central Catheter (PICC) Occlusions · Phase 2 · unknown

Other Centre Hospitalier Universitaire Dijon trials

Trials by the same sponsor.

NCT06608004 — Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis · recruiting
NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
NCT06776848 — A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With · Phase 1, PHASE2 · recruiting
NCT06347302 — Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment · NA · completed
NCT06252415 — Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With C · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01962116 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Dijon
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01962116.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing